Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 15:2:100007.
doi: 10.1016/j.crphar.2020.100007. eCollection 2021.

Tuberculosis and pharmacological interactions: A narrative review

Niccolò Riccardi  1   2 , Diana Canetti  1   3 , Paola Rodari  2 , Giorgio Besozzi  1 , Laura Saderi  1   4 , Marco Dettori  4 , Luigi R Codecasa  1   5 , Giovanni Sotgiu  1   4
Affiliations
Review

Tuberculosis and pharmacological interactions: A narrative review

Niccolò Riccardi et al. Curr Res Pharmacol Drug Discov. .

Abstract

Even if major improvements in therapeutic regimens and treatment outcomes have been progressively achieved, tuberculosis (TB) remains the leading cause of death from a single infectious microorganism. To improve TB treatment success as well as patients' quality of life, drug-drug-interactions (DDIs) need to be wisely managed. Comprehensive knowledge of anti-TB drugs, pharmacokinetics and pharmacodynamic (PK/PD) parameters, potential patients' changes in absorption and distribution, possible side effects and interactions, is mandatory to built effective anti-TB regimens. Optimization of treatments and adherence to international guidelines can help bend the curve of TB-related mortality and, ultimately, decrease the likelihood of treatment failure and drop-out during anti-TB treatment. Aim of this paper is to describe the most relevant DDIs between anti-TB and other drugs used in daily clinical practice, providing an updated and "easy-to-use" guide to minimize adverse effects, drop-outs and, in the long run, increase treatment success.

Keywords: Clinical use; Drug-drug interactions; TB treatment; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Abulfathi A.A., Donald P.R., Adams K., Svensson E.M., Diacon A.H., Reuter H. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance. Br. J. Clin. Pharmacol. 2020 May 29 doi: 10.1111/bcp.14395. - DOI - PMC - PubMed
    1. Acocella G, Bonollo L, Garimoldi M, et al. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut. 1972;13:47–53. - PMC - PubMed
    1. Aitio M.L., Mansury L., Tala E., Haataja M., Aitio A. The effect of enzyme induction on the metabolism of disopyramide in man. Br. J. Clin. Pharmacol. 1981 Mar;11(3):279–285. doi: 10.1111/j.1365-2125.1981.tb00535.x. PMID: 7213529; PMCID: PMC1401616. - DOI - PMC - PubMed
    1. Alffenaar J.W., Bolhuis M., van Hateren K., Sturkenboom M., Akkerman O., de Lange W., Greijdanus B., van der Werf T., Touw D. Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother. 2015 Sep;59(9):5675–5680. doi: 10.1128/AAC.00276-15. Epub 2015 Jul 6. PMID: 26149993; PMCID: PMC4538542. - DOI - PMC - PubMed
    1. Andries K., Villellas C., Coeck N., Thys K., Gevers T., et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One. 2014;9(7) doi: 10.1371/journal.pone.0102135. - DOI - PMC - PubMed

LinkOut - more resources